Stifel Financial Corp Hutchmed (China) LTD Transaction History

Stifel Financial Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.59 - $20.77 $265,671 - $642,374	-30,928 Reduced 75.21%	10,193 $129,000
Q1 2022 May 13, 2022	BUY	$15.52 - $35.65 $12,571 - $28,876	810 Added 2.01%	41,121 $777,000
Q4 2021 Feb 14, 2022	BUY	$28.89 - $35.33 $38,857 - $47,518	1,345 Added 3.45%	40,311 $1.42 Million
Q3 2021 Nov 15, 2021	BUY	$35.66 - $42.94 $41,472 - $49,939	1,163 Added 3.08%	38,966 $1.43 Million
Q2 2021 Aug 13, 2021	BUY	$23.7 - $39.27 $14,291 - $23,679	603 Added 1.62%	37,803 $1.49 Million
Q1 2021 May 14, 2021	BUY	$27.01 - $36.8 $14,990 - $20,424	555 Added 1.51%	37,200 $1.05 Million
Q4 2020 Feb 12, 2021	BUY	$27.51 - $34.36 $23,466 - $29,309	853 Added 2.38%	36,645 $1.17 Million
Q3 2020 Nov 16, 2020	BUY	$25.8 - $34.61 $19,633 - $26,338	761 Added 2.17%	35,792 $1.16 Million
Q2 2020 Aug 14, 2020	BUY	$17.65 - $28.05 $38,371 - $60,980	2,174 Added 6.62%	35,031 $966,000
Q1 2020 May 14, 2020	BUY	$15.19 - $29.51 $8,430 - $16,378	555 Added 1.72%	32,857 $555,000
Q4 2019 Feb 13, 2020	SELL	$17.17 - $25.95 $12,843 - $19,410	-748 Reduced 2.26%	32,302 $804,000
Q3 2019 Nov 13, 2019	BUY	$17.84 - $22.69 $589,612 - $749,904	33,050 New	33,050 $566,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Stifel Financial Corp with notifications on news.